Cancer incidence trends in 2021 largely returned to what they were before the COVID-19 pandemic, according to a study by researchers at the National Institutes of Health (NIH).
FDA approves first two interchangeable biosimilars to Regeneron’s blockbuster Eylea
Eylea will eventually have competition in the US, as the FDA approved two interchangeable biosimilars. Monday’s approvals for Biocon Biologics’ Yesafili and Samsung Bioepis and
May 21, 2024